

In the claims:

Please cancel without prejudice claims 121, 122, 126, 136-148, and 151-195.

Please amend the claims as follows:

113. (Amended) An isolated [or recombinant] polypeptide comprising an amino acid sequence that is identical to an amino acid sequence of a naturally occurring *H. pylori* polypeptide, wherein said isolated polypeptide has [having] at least 60 percent sequence identity with SEQ ID NO: 764], wherein said sequence identity is determined by [the BLASTP algorithm, or by

(1) aligning the amino acid sequence with SEQ ID NO:764 to identify the number of matching positions shared by the amino acid sequence and SEQ ID NO:764,

(2) dividing the number of matching positions by the total number of amino acids in SEQ ID NO:764, and

(3) multiplying the dividend by 100].

114. (Amended) The isolated [or recombinant] polypeptide of claim 113 comprising an amino acid sequence having at least 70 percent sequence identity with SEQ ID NO: 764.

115. (Amended) The isolated [or recombinant] polypeptide of claim 113 comprising an amino acid sequence having at least 80 percent sequence identity with SEQ ID NO: 764.

116. (Amended) The isolated [or recombinant] polypeptide of claim 113 comprising an amino acid sequence having at least 90 percent sequence identity with SEQ ID NO: 764.

117. (Amended) The isolated [or recombinant] polypeptide of claim 113 comprising an amino acid sequence having at least 95 percent sequence identity with SEQ ID NO: 764.

118. (Amended) The isolated [or recombinant] polypeptide of claim 113 comprising an amino acid sequence having at least 98 percent sequence identity with SEQ ID NO: 764.

119. (Amended) The isolated [or recombinant] polypeptide of claim 113 comprising an amino acid sequence having at least 99 percent sequence identity with SEQ ID NO: 764.

120. (Amended) An isolated [or recombinant] polypeptide comprising an amino acid sequence that is identical to an amino acid sequence of a naturally occurring *H. pylori* polypeptide, wherein said isolated polypeptide comprises at least 10 amino acid residues and is encoded by a nucleotide sequence which hybridizes under high stringency [stringent] conditions to the complement of a nucleotide sequence encoding SEQ ID NO: 764.

123. (Amended) An isolated [or recombinant] polypeptide of any one of claims 196-204 [113-120] which is a recombinant polypeptide.

125. (Amended) An isolated [immunogenic] polypeptide comprising at least [5] 10 consecutive amino acid residues of SEQ ID NO: 764.

127. (Amended) The isolated [immunogenic] polypeptide of claim 125 comprising at least about 12 consecutive amino acid residues of SEQ ID NO: 764.

128. (Amended) The isolated [immunogenic] polypeptide of claim 125 comprising at least about 16 consecutive amino acid residues of SEQ ID NO: 764.

129. (Amended) The isolated [immunogenic] polypeptide of claim 125 comprising at least about 20 consecutive amino acid residues of SEQ ID NO: 764.

130. (Amended) The isolated [immunogenic] polypeptide of claim 125 comprising at least about 50 consecutive amino acid residues of SEQ ID NO: 764.

131. (Amended) The isolated [immunogenic] polypeptide of claim 125 comprising at least about 100 consecutive amino acid residues of SEQ ID NO: 764.

132. (Amended) A fusion protein comprising a [an isolated or recombinant] polypeptide of any one of claims 113[-120], 120 or 196-204 [operably linked to] and an additional amino acid sequence.

134. (Amended) A fusion protein comprising [an isolated or recombinant] a polypeptide of claim [121, operably linked to] 125 and an additional amino acid sequence.

149. (Amended) A composition comprising a [an isolated or recombinant] polypeptide of any one of claims 113[-120], 120 or 196-204 and a pharmaceutically acceptable carrier.

150. (Amended) A composition comprising a [an isolated or recombinant] polypeptide of claim [121] 125 and a pharmaceutically acceptable carrier.

Please add new claims 196-213 as follows:

196. An isolated polypeptide comprising at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:764, said isolated polypeptide comprising an amino acid sequence having at least 60 percent sequence identity with SEQ ID NO: 764.

197. An isolated polypeptide comprising at least one antigenic determinant of the polypeptide set forth in SEQ ID NO:764, said isolated polypeptide comprising an amino acid sequence having at least 60 percent sequence identity with SEQ ID NO: 764.

198. An isolated polypeptide that is immunologically crossreactive with the polypeptide set forth in SEQ ID NO:764, said isolated polypeptide comprising an amino acid sequence having at least 60 percent sequence identity with SEQ ID NO: 764.

199. An isolated polypeptide comprising at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:764, wherein said isolated polypeptide comprises at least 10 amino acid residues and is encoded by a nucleotide sequence which hybridizes under high stringency conditions to the complement of a nucleotide sequence encoding SEQ ID NO:764.

200. An isolated polypeptide comprising at least one antigenic determinant of the polypeptide set forth in SEQ ID NO:764, wherein said isolated polypeptide comprises at least 10 amino acid residues and is encoded by a nucleotide sequence which hybridizes under high stringency conditions to the complement of a nucleotide sequence encoding SEQ ID NO:764.

201. An isolated polypeptide that is immunologically crossreactive with the polypeptide set forth in SEQ ID NO:764, wherein said isolated polypeptide comprises at least 10 amino acid residues and is encoded by a nucleotide sequence which hybridizes under high stringency conditions to the complement of a nucleotide sequence encoding SEQ ID NO:764.

202. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 764, wherein said polypeptide comprises at least one epitope recognized by a T cell receptor specific for the polypeptide set forth in SEQ ID NO:764.

203. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 764, wherein said polypeptide comprises at least one antigenic determinant of the polypeptide set forth in SEQ ID NO:764.

204. An isolated polypeptide comprising at least 10 consecutive amino acid residues of SEQ ID NO: 764, wherein said polypeptide is immunologically crossreactive with the polypeptide set forth in SEQ ID NO:764.

205. The isolated polypeptide of any one of claims 113 or 196-198 wherein said sequence identity with SEQ ID NO:764 is determined by

(1) aligning the amino acid sequence with SEQ ID NO:764 to identify the number of matching positions shared by the amino acid sequence and SEQ ID NO:764,

(2) dividing the number of matching positions by the total number of amino acids in SEQ ID NO:764, and

(3) multiplying the dividend by 100.

206. The isolated polypeptide of any one of claims 113 or 196-198 comprising at least 10 amino acid residues.

47
cont. Sub
41 207. The isolated polypeptide of any one of claims 113, 120 or 196-204 comprising at least about 12 amino acid residues.

208. The isolated polypeptide of any one of claims 113, 120 or 196-204 comprising at least about 16 amino acid residues.

209. The isolated polypeptide of any one of claims 113, 120 or 196-204 comprising at least about 20 amino acid residues.

210. The isolated polypeptide of any one of claims 113, 120 or 196-204 comprising at least about 50 amino acid residues.

211. The isolated polypeptide of any one of claims 113, 120 or 196-204 comprising at least about 100 amino acid residues.